Citations 2
Liver transplantation from SARS-CoV-2-positive deceased donors: Thrombotic risk, graft implications, and the impact of perioperative management
Abdulhamid, Asim, Rosen, Charles, Ryan, Randi , Liese, Michael
Liver Transplantation | September 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension
Cartin‐Ceba, Rodrigo , Swanson, Karen L., Vargas, Hugo E. , Aqel, Bashar , Taner, Timuçin , Nyberg, Scott L. , Rosen, Charles B. , Krowka, Michael J. , Swanson, Karen, Vargas, Hugo, Nyberg, Scott, Rosen, Charles, Cajigas, Héctor , DuBrock, Hilary, Vargas, Hugo E , Burger, Charles D. , Aqel, Bashar A. , Keaveny, Andrew P. , Heimbach, Julie K. , DuBrock, Hilary M.
Transplantation | October 16, 2020 | Volume: 105 | Issue: 10 | Pages: 2283-2290
Background. Portopulmonary hypertension (POPH) is the presence of pulmonary arterial (PA) hypertension in patients with portal hypertension and is associated with significant morbidity and mortality. In a cohort of POPH patients, we describe the clinical outcomes of POPH patients who underwent liver transplantation (LT). Methods. Retrospectively collected data from a prospectively assembled cohort of all consecutive POPH adults evaluated in 3 transplant centers from 1996 to 2019. Results. From a cohort of 228 POPH patients, 50 patients underwent LT. Significant hemodynamic improvement after PA-targeted therapy was observed, with 58% receiving only monotherapy pretransplant. After LT, 21 (42%) patients were able to discontinue and remained off PA-targeted therapy. The 1-, 3-, and 5-y unadjusted survival rates after LT were 72%, 63%, and 60%, respectively. An elevated pulmonary vascular resistance (PVR) before LT was associated with worse survival rate (HR, 1.91; 95% CI, 1.07-3.74, P = 0.04). No survival difference was observed in those granted MELD exception or transplants performed before or after the year 2010. Conclusions. Significant number of POPH patients discontinued PA-targeted therapy after LT. Higher PVR before LT was associated with worse survival, as was monotherapy use. Despite effective PA-targeted therapies, POPH survival outcomes after LT in our cohort were modest and may reflect the need for more aggressive therapy.